We have located links that may give you full text access.
Sulphidopeptide leukotrienes in asthma.
Clinical Science (1979-) 1993 May
No single mediator is responsible for the clinical and pathological events in bronchial asthma. Nevertheless, there is now substantial evidence that the sulphidopeptide leukotrienes play an important role in the pathophysiology of the disease. They are potent in eliciting bronchoconstriction, mucus production and vasodilatation, and may enhance the airways hyperresponsiveness that is characteristic of the disease. The sulphidopeptide leukotrienes are present in the airways of asthmatic patients and their release has been demonstrated in acute severe asthma. They are released during asthmatic attacks provoked by a range of stimuli. The evidence from studies using sulphidopeptide leukotriene antagonists and 5-LO inhibitors suggests strongly that sulphidopeptide leukotrienes contribute to the resting asthmatic airways tone and to the asthmatic responses elicited by exercise, allergen, aspirin and cold, dry air challenges. These mediators may also contribute to the airways hyperresponsiveness induced by allergen challenge of sensitized subjects. Preliminary results indicate that the administration of leukotriene receptor antagonists and 5-LO inhibitors may benefit patients with chronic asthma. Further studies are now needed to define better the role of these novel drugs in the management of the disease.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app